Transition Industries Signs Heads of Agreement with Bonatti S.p.A for Critical Infrastructure on Pacifico Mexinol Project
14.8.2025 16:05:00 EEST | Business Wire | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects, signed a Heads of Agreement contract with Bonatti, an international contractor specializing in the energy sector, for critical infrastructure on the Pacifico Mexinol project in Sinaloa, Mexico.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814767897/en/
Pacifico Mexinol is poised to be the world’s largest standalone ultra-low carbon chemical production facility in the world, with an output of 6,130 metric tons of methanol (MT) per day.
Under the terms of the Heads of Agreement, which includes a lump sum binding price, Bonatti will be responsible for the detailed engineering, procurement, construction, pre-commissioning, commissioning, and startup for the upgrade of the port facilities and jetty at the Terminal Transoceánica de Topolobampo, S.A. de C.V. (“TTT”) port area where all methanol loading operations for export will occur. Bonatti will also be responsible for detailed engineering, procurement, construction, pre-commissioning, commissioning, and startup of the methanol transfer and vapor recovery underground pipelines and dual fiber optic cables between the Methanol main process plant and the Mexinol port site.
The agreement also provides Bonatti with the opportunity to build the project’s closed-loop water pipeline system from the JAPAMA oxidation pools to the site, making the Pacifico Mexinol site one of the world's largest applications of industrial water reuse from municipal effluent. This system treats and recycles municipal wastewater for all project needs in order to avoid tapping into freshwater sources or negatively impacting the Bay of Ohuira, thereby reducing the project’s environmental impact.
Balmore Brito, Pacifico Mexinol Project Director and Head of Engineering and Technology for Transition Industries said: “We are proud to have Bonatti, a world-leader in pipeline EPCs, as part of our execution team. Their international expertise coupled with their local field experience and knowledge operating in Ahome Municipality, Sinaloa, is good for the project and the local communities near where we operate. Bonatti shares our unwavering commitment to environmental and social sustainability.”
Gustavo Blejer, Bonatti’s Commercial Director for the Americas, said: “We are thrilled to be part of this flagship project, which marks an important step toward decarbonization. This is a great opportunity to combine Bonatti’s global expertise with our strong local experience, and to contribute meaningfully to the development of Ahome, Sinaloa, and Mexico.”
Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. When it initiates operations in 2029, Pacifico Mexinol is expected to be the largest single ultra-low carbon methanol facility in the world – producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture.
ABOUT TRANSITION INDUSTRIES
Transition Industries LLC, based in Houston, Texas, is a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America to address climate change and promote environmental and social sustainability. For additional information about Pacifico Mexinol or Transition Industries, email inquiries@transitionind.com.
ABOUT BONATTI
Bonatti is an international contractor with over 80 years of experience in the energy and mining sectors. The company’s expertise covers the full project lifecycle—from engineering, procurement, and construction to the operation and maintenance of plants and pipelines. Bonatti is actively engaged in the energy transition and water sustainability sectors. Ongoing projects include carbon capture, hydrogen, biofuel, and solar power plants, as well as water infrastructure developments designed to reduce freshwater use in mining operations. With operations spanning Canada, Mexico, and Chile, Bonatti has established a strong presence across the Americas. Having generated USD 2.5B+ in cumulative revenues, the company is recognized as Mexico’s leading midstream contractor. For more information, visit www.bonatti.it.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250814767897/en/
Contacts
Transition Industries Press Relations
Karin Nunan
Head of Corporate Affairs
knunan@transitionind.com - inquiries@transitionind.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom